A5042290277- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
- Central Venous Catheters and Hemodialysis
- Acute Myocardial Infarction Research
- Diagnosis and Treatment of Venous Diseases
- Acute Ischemic Stroke Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac Arrhythmias and Treatments
- Cancer Treatment and Pharmacology
- Antiplatelet Therapy and Cardiovascular Diseases
- Ultrasound in Clinical Applications
- Cardiac tumors and thrombi
- Cardiovascular Issues in Pregnancy
- Blood properties and coagulation
- Reliability and Agreement in Measurement
- Health Systems, Economic Evaluations, Quality of Life
- Peripheral Artery Disease Management
- Hemophilia Treatment and Research
- Meta-analysis and systematic reviews
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood Pressure and Hypertension Studies
- Case Reports on Hematomas
- Travel-related health issues
- Clinical practice guidelines implementation
Amsterdam University Medical Centers
2018-2025
University of Amsterdam
2016-2025
Rabin Medical Center
2024
Amsterdam UMC Location University of Amsterdam
2012-2023
Inserm
2014-2023
Tergooi
2023
University Medical Center
2023
Utrecht University
2023
University Medical Center Utrecht
2014-2023
Université d'Angers
2023
Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and continued treatment, without the need laboratory monitoring.
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective standard anticoagulant therapy for the treatment deep-vein thrombosis, without need laboratory monitoring. This approach may also simplify pulmonary embolism.
Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism.In this randomized, double-blind study, we compared apixaban (at a dose 10 mg twice daily for 7 days, followed by 5 6 months) with conventional therapy (subcutaneous enoxaparin, warfarin) 5395 patients acute thromboembolism. The primary efficacy outcome was recurrent symptomatic thromboembolism or death related to principal safety outcomes were major bleeding alone and plus...
Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.In a randomized, double-blind, noninferiority study, we randomly assigned acute thromboembolism, who had initially received heparin, receive at dose of 60 mg once daily, or 30 daily (e.g., case creatinine clearance 50 ml per minute body weight below kg), warfarin. Patients study drug for 3 12 months. The primary efficacy outcome was recurrent symptomatic...
Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of with direct oral anticoagulant agents unclear.
Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may option for the extended treatment of venous thromboembolism.
An intravenous course of standard (unfractionated) heparin with the dose adjusted to prolong activated partial-thromboplastin time a desired length is initial in-hospital treatment for patients deep-vein thrombosis, but fixed-dose subcutaneous low-molecular-weight appears be as effective and safe. Because latter can given on an outpatient basis, we compared two treatments in symptomatic outpatients proximal-vein thrombosis no signs pulmonary embolism.
ContextPrevious studies have evaluated the safety of relatively complex combinations clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.ObjectiveTo assess effectiveness a simplified algorithm using dichotomized rule, D-dimer testing, computed tomography (CT) embolism.Design, Setting, PatientsProspective cohort study consecutive clinically acute embolism, conducted 12 centers Netherlands from November 2002 through December 2004. The population 3306...
In 220 consecutive outpatients with clinically suspected deep-vein thrombosis of the leg, we compared contrast venography real-time B-mode ultrasonography, using single criterion vein compressibility ultrasound transducer probe. The common femoral and popliteal veins were evaluated for full (no thrombosis) noncompressibility (thrombosis). Both fully compressible in 142 143 patients normal venograms (specificity, 99 percent; 95 percent confidence interval, 97 to 100). All 66 proximal-vein had...
Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There controversy whether known malignancy a risk factor recurrences and bleeding complications during this treatment. Furthermore, incidence such events in these dependent on achieved International Normalized Ratio (INR). The aim study was to assess thromboembolic recurrence major among thromboembolism relation both INR.In retrospective analysis, INR-specific oral...
In contrast to the established relation between overt cancer and subsequent venous thromboembolism, it is unclear whether symptomatic deep-vein thrombosis associated with a risk of malignant disease.
Tumor necrosis factor has been implicated in the activation of blood coagulation septicemia, a condition commonly associated with intravascular and disturbances hemostasis. To evaluate early dynamics route vivo coagulative response to tumor factor, we performed controlled study six healthy men, monitoring common intrinsic pathways highly sensitive specific radioimmunoassays.
Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that bind directly to and block its interaction with substrates. Four parenteral DTIs have been approved by the FDA — hirudin argatroban for heparin-induced thrombocytopenia, bivalirudin as an alternative heparin in percutaneous coronary intervention, desirudin prophylaxis against venous thromboembolism hip replacement. This article discusses clinical data on this important medications.
Background: The current standard initial therapies for deep venous thrombosis are low-molecular-weight heparin and unfractionated heparin. In a dose-ranging study of patients with symptomatic thrombosis, fondaparinux had efficacy safety profile similar to those (dalteparin). Objective: To evaluate whether has enoxaparin in thrombosis. Design: Randomized, double-blind study. Setting: 154 centers worldwide. Patients: 2205 acute Intervention: Fondaparinux, 7.5 mg (5.0 weighing <50 kg 10.0 >100...
Studies in cancer patients with venous thromboembolism suggested that low molecular weight heparin may prolong survival. In a double-blind study, we evaluated the effect of on survival advanced malignancy without thromboembolism.Patients metastasized or locally solid tumors were randomly assigned to receive 6-week course subcutaneous nadroparin placebo. The primary efficacy analysis was based time from random assignment death. safety outcome major bleeding.In total, 148 allocated and 154...
The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety oral rivaroxaban administered for an extended period, as compared subcutaneous enoxaparin a standard followed by placebo.